M.D. Anderson Gynecologic SPORE for Uterine Cancers

Summary

Principal Investigator: KAREN HSIEH LU
Abstract: The overall goal of the Gynecologic Cancer Specialized Program of Research Excellence (SPORE) at MD Anderson Cancer Center is to conduct highly innovative translational research for the prevention and treatment of uterine cancers. Encompassed within this overall goal are the following goals of the program: 1) to develop novel therapeutic strategies for advanced and recurrent endometrial cancer, 2) to promote novel strategies for chemoprevention of endometrial cancer in high risk cohorts, including obese women, and 3) to incorporate molecular diagnostics into clinical decision-making. Over the last 5 years, as the only Uterine Cancer SPORE, we established a highly productive uterine cancer translational research community that is unparalleled in breadth and depth. This Proposal includes 4 Projects that display high translational impact and outstanding scientific merit, led by experienced translational scientists. Project 1, "Metformin for the Chemoprevention of Endometrial Cancer in Obese, Insulin-Resistant Women," includes a chemoprevention trial using metformin for obese, insulin-resistant women. Project 2, "Use of Endometrial Biomarkers for Prediction of Advanced Disease," seeks to determine if a panel of molecular biomarkers discovered during the first five years of the SPORE can address a specific and important clinical dilemma facing surgeons caring for women with endometrial cancer. Project 3, "EphA2 Targeting in Uterine Carcinoma," focuses on a novel therapeutic target, EphA2. EphA2 is overexpressed in a substantial proportion of uterine cancers, is associated with poor overall survival, and has been shown to regulate angiogenesis. This project will include a phase Ib clinical trial of an immunoconjugate that links an anti-cancer therapeutic to an antibody against EphA2. Project 4 "Targeting the PISK Signaling Pathway in Endometrial Carcinoma," focuses on the role of the phosphatidylinositol-3-kinase PI3K/PTEN/AKT/mT0R signaling pathway in endometrial tumorigenesis. Preliminary data suggests that mutations exist in multiple nodes of this pathway, and that responsiveness to pathway inhibitors may differ based on mutation. This project will include a phase II clinical trial assessing the efficacy of the PI3K inhibitor, GSK2126458A, in advanced endometrial carcinoma. Four Cores will support these projects. Core A (Administrative Core), Core B (Pathology Core), Core C Biomarkers Core, and Core D (Biostatistics and Bioinformatics Core).
Funding Period: 2003-09-14 - 2015-08-31
more information: NIH RePORT

Top Publications

  1. pmc Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing
    Angela N Bartley
    Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Prev Res (Phila) 5:320-7. 2012
  2. pmc Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies
    Justin N Bottsford-Miller
    Departments of Gynecologic Oncology and Cancer Biology, University of Texas MD Anderson Cancer Center, Unit 1362, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 30:4026-34. 2012
  3. pmc Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer
    Han Liang
    Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Genome Res 22:2120-9. 2012
  4. pmc Identifying molecular drivers of gastric cancer through next-generation sequencing
    Han Liang
    Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX 77030, USA Electronic address
    Cancer Lett 340:241-6. 2013
  5. pmc Contemporary use of bevacizumab in ovarian cancer
    Takahito M Miyake
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030, USA
    Expert Opin Biol Ther 13:283-94. 2013
  6. pmc Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer
    Cristina Ivan
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Gynecol Oncol 128:506-11. 2013
  7. pmc Repurposing the Pap smear: one step closer to gynecologic cancer screening
    Shannon N Westin
    Department of Gynecologic Oncology and Reproductive Medicine, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Sci Transl Med 5:167ps1. 2013
  8. pmc Why stress is BAD for cancer patients
    Archana S Nagaraja
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    J Clin Invest 123:558-60. 2013
  9. pmc Src activation by β-adrenoreceptors is a key switch for tumour metastasis
    Guillermo N Armaiz-Pena
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Nat Commun 4:1403. 2013
  10. pmc Latest research and treatment of advanced-stage epithelial ovarian cancer
    Robert L Coleman
    Department of Gynecologic Oncology and Reproductive Medicine, University of Texas, MD Anderson Cancer Center, 1155 Herman Pressler Drive, Houston, TX 77030, USA rcoleman mdanderson org
    Nat Rev Clin Oncol 10:211-24. 2013

Research Grants

Detail Information

Publications128 found, 100 shown here

  1. pmc Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing
    Angela N Bartley
    Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Prev Res (Phila) 5:320-7. 2012
    ..Thus, a major consequence of the use of immunohistochemistry by itself as a screen is the failure to identify colorectal and endometrial cancer patients who likely have Lynch syndrome...
  2. pmc Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies
    Justin N Bottsford-Miller
    Departments of Gynecologic Oncology and Cancer Biology, University of Texas MD Anderson Cancer Center, Unit 1362, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 30:4026-34. 2012
    ..Insights gained through this work may offer solutions for personalizing antiangiogenesis approaches and improving the outcome of patients with cancer...
  3. pmc Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer
    Han Liang
    Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Genome Res 22:2120-9. 2012
    ..Our study presents the first unbiased view of somatic coding mutations in endometrial cancer and provides functional evidence for diverse driver genes and mutations in this disease...
  4. pmc Identifying molecular drivers of gastric cancer through next-generation sequencing
    Han Liang
    Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX 77030, USA Electronic address
    Cancer Lett 340:241-6. 2013
    ..We also discuss the challenges and future directions of such efforts. ..
  5. pmc Contemporary use of bevacizumab in ovarian cancer
    Takahito M Miyake
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030, USA
    Expert Opin Biol Ther 13:283-94. 2013
    ..Therefore, novel treatment strategies to increase primary efficacy, decrease recurrence after primary treatment and improve the response rate for recurrent disease are needed...
  6. pmc Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer
    Cristina Ivan
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Gynecol Oncol 128:506-11. 2013
    ..We used The Cancer Genome Atlas (TCGA) data to study the clinical relevance of epigenetic modifications of Notch superfamily genes...
  7. pmc Repurposing the Pap smear: one step closer to gynecologic cancer screening
    Shannon N Westin
    Department of Gynecologic Oncology and Reproductive Medicine, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Sci Transl Med 5:167ps1. 2013
    ..In this issue of Science Translational Medicine, Kinde and colleagues use advanced sequencing technology to evaluate DNA to screen for gynecologic malignancies...
  8. pmc Why stress is BAD for cancer patients
    Archana S Nagaraja
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    J Clin Invest 123:558-60. 2013
    ..In this issue, Hassan et al. focus on the signaling and biological effects induced by stress hormones that lead to tumor cell evasion from apoptosis, resulting in prostate cancer progression...
  9. pmc Src activation by β-adrenoreceptors is a key switch for tumour metastasis
    Guillermo N Armaiz-Pena
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Nat Commun 4:1403. 2013
    ..Collectively, these data provide a pivotal molecular target for disrupting neural signalling in the tumour microenvironment...
  10. pmc Latest research and treatment of advanced-stage epithelial ovarian cancer
    Robert L Coleman
    Department of Gynecologic Oncology and Reproductive Medicine, University of Texas, MD Anderson Cancer Center, 1155 Herman Pressler Drive, Houston, TX 77030, USA rcoleman mdanderson org
    Nat Rev Clin Oncol 10:211-24. 2013
    ..This Review presents and reviews the contemporary management of the disease spectrum termed epithelial 'ovarian' cancer and describes the direction and early results of clinical investigation...
  11. ncbi Functional analysis of ectodermal β-catenin during external genitalia formation
    Ahmad Reza Mazahery
    Department of Developmental Genetics, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan
    Congenit Anom (Kyoto) 53:34-41. 2013
    ..Thus, β-catenin is shown to perform dual functions, initially as an adhesion molecule and later on as a possible transcription factor...
  12. pmc Chemopreventive effects of metformin on obesity-associated endometrial proliferation
    Qian Zhang
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
    Am J Obstet Gynecol 209:24.e1-24.e12. 2013
    ..In this study, we investigate whether pharmacologic agents that modulate insulin sensitivity or normalize insulin levels will diminish the proliferative response to estrogen...
  13. pmc HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines
    Jinping Li
    Department of Biomedical Science, School of Medicine, Mercer University, Savannah, GA 31404, USA
    Int J Mol Sci 14:6026-43. 2013
    ..This study provides evidence that HE4 overexpression directly impacts tumor progression in endometrial cancer...
  14. pmc ATP11B mediates platinum resistance in ovarian cancer
    Myrthala Moreno-Smith
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Invest 123:2119-30. 2013
    ..In conclusion, inhibition of ATP11B expression could serve as a therapeutic strategy to overcome cisplatin resistance...
  15. pmc Biologic effects of dopamine on tumor vasculature in ovarian carcinoma
    Myrthala Moreno-Smith
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Neoplasia 15:502-10. 2013
    ..These findings could have implications for blocking the stimulatory effects of chronic stress on tumor growth...
  16. pmc A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study
    Robert L Coleman
    Dept of Gynecologic Oncology and Reproductive Medicine, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 127:538-43. 2012
    ..We evaluated activity and toxicity of aflibercept in recurrent/persistent endometrial cancer patients. Biomarkers and association with clinical characteristics and outcome were explored...
  17. pmc Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma
    Mian M K Shahzad
    Department of Gynecologic Oncology, U T M D Anderson Cancer Center, Houston, TX 77030, United States
    Cancer Lett 330:123-9. 2013
    ..HORMAD1 gene silencing resulted in significantly reduced VEGF protein levels and microvessel density compared to controls. Our data suggest that HORMAD1 may be an important therapeutic target...
  18. pmc Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible
    Karuna Garg
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Gynecol Pathol 31:48-56. 2012
    ..Our study shows that evaluation of PTEN loss by immunohistochemistry is highly reproducible with the application of standard immunohistochemical techniques and simple scoring criteria...
  19. pmc Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes
    Li E Wang
    Department of Epidemiology, Unit 1365, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Cancer Res Clin Oncol 138:377-85. 2012
    ..In this candidate pathway analysis, we investigated associations between genetic variations in these two pathways and both risk and clinical outcomes of endometrial cancer...
  20. pmc Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors
    Ann H Klopp
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:771-82. 2012
    ..We hypothesized that intra-abdominal visceral adipose tissue may contain a uniquely tumor-promoting population of ASC to account for the relationship between excess visceral adipose tissue and mortality of intra-abdominal cancers...
  21. pmc A novel platform for detection of CK+ and CK- CTCs
    Chad V Pecot
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Discov 1:580-6. 2011
    ..Collectively, our study provides a new method for highly efficient capture of previously unrecognized populations of CTCs...
  22. pmc Personalized therapy in endometrial cancer: challenges and opportunities
    Shannon N Westin
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 13:1-13. 2012
    ..traditional chemotherapy or radiation treatment. This review will discuss relevant pathways to target in endometrial cancer as well as the challenges that arise during development of a personalized oncology approach...
  23. pmc Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing
    Bojana Djordjevic
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Mod Pathol 25:699-708. 2012
    ..Therefore, for clinical purposes, immunohistochemistry appears to be a preferable technique for identifying endometrial tumors with loss of PTEN function...
  24. pmc Paraneoplastic thrombocytosis in ovarian cancer
    Rebecca L Stone
    Department of Gynecologic Oncology and Reproductive Medicine, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    N Engl J Med 366:610-8. 2012
    ..The mechanisms of paraneoplastic thrombocytosis in ovarian cancer and the role that platelets play in abetting cancer growth are unclear...
  25. pmc Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer
    Duangmani Thanapprapasr
    Department of Gynecologic Oncology, University of Texas, M D Anderson Cancer Center, 1155 Herman Pressler Dr CPB 6 3271, Houston, TX 77030, USA
    Curr Pharm Des 18:2713-9. 2012
    ..Herein, we review the role of these new targets in tumor angiogenesis and the rationale for further clinical development...
  26. pmc Improved cellular specificity of plasmonic nanobubbles versus nanoparticles in heterogeneous cell systems
    Ekaterina Y Lukianova-Hleb
    Department of Biochemistry and Cell Biology, Rice University, Houston, Texas, United States of America
    PLoS ONE 7:e34537. 2012
    ..Thus PNBs may be a universal method and nano-agent that overcome the problem of non-specific uptake of NPs by non-target cells and improve the specificity of NP-based diagnostics, therapeutics and theranostics at the cell level...
  27. pmc Targeting angiogenesis in gynecologic cancers
    Behrouz Zand
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030, USA
    Hematol Oncol Clin North Am 26:543-63, viii. 2012
    ....
  28. pmc Somatic deletions of the polyA tract in the 3' untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas
    Ma Deqin
    Division of Pathology and Laboratory Medicine, University of Texas M D Anderson Cancer Center, 8515 Fannin Street, Houston, TX 77054, USA
    Arch Pathol Lab Med 136:510-6. 2012
    ..This phenomenon has not been reported in other MSI-H tumors...
  29. pmc Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma
    Sun Joo Lee
    Department of Gynecologic Oncology and Reproductive Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:4114-21. 2012
    ....
  30. pmc Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Gynecol Oncol 127:70-4. 2012
    ..The Gynecologic Oncology Group (GOG) conducted a Phase II trial to evaluate the efficacy and safety of dasatinib, an oral SRC-family inhibitor in EOC/PPC, and explored biomarkers for possible association with clinical outcome...
  31. pmc Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome
    Karen H Lu
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 6:774-81. 2013
    ..These results show that women with Lynch syndrome do show an endometrial response to short-term exogenous progestins, suggesting that OCP and depo-MPA may be reasonable chemopreventive agents in this high-risk patient population...
  32. ncbi Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways
    Vijaya Galic
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, 161 Ft Washington Avenue, New York, NY 10032, USA
    Curr Cancer Drug Targets 13:698-707. 2013
    ....
  33. pmc Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma
    Koji Matsuo
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA Norris Comprehensive Cancer Center, Los Angeles, CA, USA
    Gynecol Oncol 132:166-75. 2014
    ..We examined (i) whether PDGFRα blockade enhances the antitumor activity of taxanes in ovarian carcinoma and (ii) potential biomarkers of response to anti-PDGFRα therapy...
  34. pmc HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival
    Shi Wen Jiang
    Department of Biomedical Science, School of Medicine, Mercer University, Savannah, GA 31404, USA
    Int J Mol Sci 14:22655-77. 2013
    ..HE4 levels appear to correlate with EC patient survival in a variant-specific manner. When using HE4 as a biomarker for EC management, the effects of age should be considered...
  35. pmc Bayesian latent-class mixed-effect hybrid models for dyadic longitudinal data with non-ignorable dropouts
    Jaeil Ahn
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, U S A Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, U S A
    Biometrics 69:914-24. 2013
    ..We evaluate the performance of the proposed method using a simulation study, and apply our method to a longitudinal dyadic data set that arose from a prostate cancer trial. ..
  36. pmc Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib
    Jie Huang
    Authors Affiliations Departments of Gynecologic Oncology and Reproductive Medicine, Hematology and Oncology, Biostatistics, Cancer Biology, and Pathology, and The Center for RNA Interference and Non Coding RNAs The University of Texas MD Anderson Cancer Center, Houston, Texas
    Clin Cancer Res 20:1846-55. 2014
    ..Dasatinib is a multikinase inhibitor that targets EphA2 and other kinases. However, reliable predictive markers and a better understanding of the mechanisms of response to this agent are needed...
  37. pmc Monocyte subpopulations in angiogenesis
    Heather J Dalton
    Authors Affiliations Departments of Gynecologic Oncology and Reproductive Medicine, Experimental Therapeutics, and Cancer Biology and Center for RNA Interference and Non Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer Res 74:1287-93. 2014
    ....
  38. pmc 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity
    Sherry Y Wu
    1 Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center MDACC, Houston, Texas 77054, USA 2
    Nat Commun 5:3459. 2014
    ..Given the previously limited success in enhancing siRNA potency with chemically modified siRNAs, our findings represent an important advance in siRNA design with the potential for application in numerous cancer types. ..
  39. pmc The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer
    Larissa A Meyer
    Departments of Gynecologic Oncology and Reproductive Medicine, Pathology Laboratory Medicine, Biostatistics, and Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX
    Int J Gynecol Cancer 24:713-7. 2014
    ..The objective of this study was to determine if biomarker expression in the PI3K/mTOR pathway or KRAS mutations would predict response to therapy with everolimus, an mTOR inhibitor...
  40. pmc CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity
    Qian Zhang
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 133:83-9. 2014
    ..We identified CGRRF1 (cell growth regulator with ring finger domain 1) as a novel metformin-responsive gene and characterized its possible role in endometrial cancer prevention...
  41. pmc Notch3 pathway alterations in ovarian cancer
    Wei Hu
    Authors Affiliations Departments of Gynecologic Oncology and Reproductive Medicine, Systems Biology, Pathology, Experimental Therapeutics, Bioinformatics and Computational Biology, Cancer Biology, Thoracic Head and Neck Medical Oncology, and the Center for RNA Interference and non Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer Res 74:3282-93. 2014
    ..Collectively, these data identify previously unknown mechanisms underlying Notch3 signaling and identify new, biomarker-driven approaches for therapy...
  42. pmc Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer
    Kshipra M Gharpure
    Authors Affiliations Departments of Gynecology Oncology, Experimental Therapeutics Program and
    Mol Cancer Ther 13:1750-7. 2014
    ..Metronomic delivery of PLGA-PRINT-docetaxel combined with CH-mEZH2 siRNA has significant antitumor activity in preclinical models of ovarian cancer...
  43. pmc Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer
    Susan L Tucker
    Authors Affiliations Departments of Bioinformatics and Computational Biology, Gynecologic Oncology and Reproductive Medicine, Experimental Therapeutics, Cancer Biology, and Center for RNA interference and non coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas and Fred Hutchinson Cancer Research Center, Seattle, Washington
    Clin Cancer Res 20:3280-8. 2014
    ..Our goal was to identify and validate molecular markers associated with high rates of residual disease...
  44. pmc Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer
    Amanda S Bruegl
    Authors Affiliations Departments of Gynecologic Oncology and Reproductive Medicine
    Cancer Prev Res (Phila) 7:686-97. 2014
    ..Universal tissue testing may be necessary to capture more individuals at risk for having Lynch syndrome...
  45. pmc Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer
    Lifeng Yang
    Laboratory for Systems Biology of Human Diseases, Rice University, Houston, TX, USA
    Mol Syst Biol 10:728. 2014
    ....
  46. pmc Role of the clinical pathology laboratory in the evaluation of endometrial carcinomas for Lynch syndrome
    Bojana Djordjevic
    Department of Pathology and Laboratory Medicine, University of Ottawa, The Ottawa Hospital, Eastern Ontario Regional Laboratory, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6 Electronic address
    Semin Diagn Pathol 31:195-204. 2014
    ..The merits of universal versus targeted tissue testing based on clinical patient history and histological tumor appearance are also addressed. ..
  47. pmc Local depletion of DNA methylation identifies a repressive p53 regulatory region in the NEK2 promoter
    Nancy H Nabilsi
    From the Department of Biochemistry and Molecular Biology, University of Florida Health Cancer Center, University of Florida College of Medicine, Gainesville, Florida 32610
    J Biol Chem 288:35940-51. 2013
    ....
  48. pmc Targeting SRC and tubulin in mucinous ovarian carcinoma
    Tao Liu
    Authors Affiliations Departments of Gynecologic Oncology and Reproductive Medicine, Genitourinary Medical Oncology, Bioinformatics and Computational Biology, and Cancer Biology Division of Cancer Medicine Center for RNA Interference and Non Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas Kinex Pharmaceuticals LLC, New York State Center of Excellence in Bioinformatics and Life Sciences, Buffalo, New York Department of General Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Department of Gynecology, Obstetrics and Gynecology, Hospital of Fudan University, Shanghai, P R China
    Clin Cancer Res 19:6532-43. 2013
    ..To investigate the antitumor effects of targeting Src and tubulin in mucinous ovarian carcinoma...
  49. pmc Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome
    Marilyn Huang
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Cancer 119:3027-33. 2013
    ..The secondary objective was to identify molecular changes that contribute to endometrial carcinogenesis in patients with LS...
  50. pmc Critical tumor suppressor function mediated by epithelial Mig-6 in endometrial cancer
    Tae Hoon Kim
    Department of Obstetrics, Gynecology and Reproductive Biology, Michigan State University College of Human Medicine, Grand Rapids, MI 49503, USA
    Cancer Res 73:5090-9. 2013
    ..In summary, our results establish that epithelial Mig-6 functions as a critical tumor suppressor that mediates the ability of progesterone to prevent the development of endometrial cancer...
  51. pmc A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis
    Massimo Masiero
    Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK
    Cancer Cell 24:229-41. 2013
    ..Collectively, these results provide insight into the regulation of tumor angiogenesis and highlight ELTD1 as key player in blood vessel formation...
  52. pmc Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer
    Amanda S Bruegl
    Department of Pathology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Curr Pharm Des 20:1655-63. 2014
    ....
  53. pmc Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies
    Gerald S Falchook
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    Invest New Drugs 31:1192-200. 2013
    ..Clinical correlates included evaluation of epigenetic changes, methylation patterns, and histone acetylation levels in peripheral blood mononuclear cells...
  54. pmc Importance of adrenergic pathways in women's cancers
    Premal H Thaker
    Gynecologic Oncology, Washington University School of Medicine, 4911 Barnes Jewish Hospital Plaza, St Louis, MO 63110, USA
    Cancer Biomark 13:145-54. 2013
    ..This review will discuss the current knowledge about the neuroendocrine stress response in gynecologic tumor biology. ..
  55. pmc Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer
    Samuel J Klempner
    Beth Israel Deaconess Medical Center, Division of Hematology Oncology, Boston, MA 02215, USA
    Expert Opin Pharmacother 14:2171-82. 2013
    ..Receptor tyrosine kinases and non-receptor tyrosine kinases play important roles in these processes and several small molecule tyrosine kinase inhibitors (TKIs) are in clinical development...
  56. pmc Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment
    Masato Nishimura
    Departments of 1Gynecologic Oncology, 2Experimental Therapeutics, 3Cancer Biology, and 4Thoracic, Head and Neck Medical Oncology, 5Graduate School of Biomedical Sciences, 6The Center for RNA Interference and Non coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas 7Division of Gynecologic Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 8Department of Obstetrics and Gynecology, The University of Tokushima, Graduate School, Tokushima, Japan 9Department of Surgery, School of Medicine, Gyeongsang National University, Jin ju, South Korea and 10Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Batiment Genopode, Lausanne, Switzerland
    Cancer Discov 3:1302-15. 2013
    ..Our data emphasize the feasibility of combined miRNA-siRNA therapy, and will have broad implications for innovative gene silencing therapies for cancer and other diseases...
  57. pmc Tumour angiogenesis regulation by the miR-200 family
    Chad V Pecot
    Department of Thoracic, Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 950, Houston, Texas 77030, USA
    Nat Commun 4:2427. 2013
    ..The role of miR-200 in blocking cancer angiogenesis in a cancer-dependent context defines its utility as a potential therapeutic agent. ..
  58. pmc Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer
    Yu Kang
    Affiliations of authors Department of Gynecologic Oncology and Repro ductive Medicine YK, WH, CI, CVP, HJD, BZ, TL, JH, NBJ, RR, MT, TM, SP, SYW, CL, YW, AKS, Center for RNAi and Non Coding RNA CI, AKS, Department of Pathology JH, Jl, and Department of Cancer Biology AKS, The University of Texas MD Anderson Cancer Center, Houston, TX Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Hospital and Institute of Obstetrics and Gynecology, Shanghai Medical College of Fudan University, Shanghai, China YK Department of General Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China TL
    J Natl Cancer Inst 105:1485-95. 2013
    ..We previously found focal adhesion kinase (FAK) inhibition sensitizes ovarian cancer to taxanes; however, the mechanisms are not well understood...
  59. pmc Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy
    David A Iglesias
    Corresponding Author Karen H Lu, Department of Gynecologic Oncology and Reproductive Medicine, 1155 Hermann Pressler Dr, Unit 1362, Houston, TX 77030
    Mol Cancer Ther 12:2847-56. 2013
    ..These studies provide a rationale for clinical trials using metformin in combination with PI3K-targeted agents for tumors harboring activating K-Ras mutations, and reveal a novel mechanism of action for metformin...
  60. pmc Nanotechnology in cancer therapy
    Burcu Aslan
    Department of Experimental Therapeutics
    J Drug Target 21:904-13. 2013
    ..In this review, we focus on several novel and improved strategies in nanocarrier design for cancer therapy...
  61. ncbi Predicting effects of kinase inhibitor in therapy for myeloid malignancies - the challenges in capturing disease heterogeneity
    Hakon Reikvam
    Haukeland University Hospital, Division for Hematology, Department of Medicine, N 5021 Bergen, Norway 55 97 50 00 55 97 29 50
    Expert Opin Investig Drugs 22:1365-70. 2013
    ....
  62. pmc Assessing the clinical utility of cancer genomic and proteomic data across tumor types
    Yuan Yuan
    1 Graduate Program in Structural and Computational Biology and Molecular Biophysics, Baylor College of Medicine, Houston, Texas, USA 2 Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 3
    Nat Biotechnol 32:644-52. 2014
    ..Our study provides a starting point and resources, including an open-access model evaluation platform, for building reliable prognostic and therapeutic strategies that incorporate molecular data. ..
  63. ncbi Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma
    Russell R Broaddus
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:87-94. 2006
    ..It was the purpose of this study to pathologically characterize a series of HNPCC associated endometrial carcinomas...
  64. pmc Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus
    Richard G Moore
    Women and Infants Hospital, Brown University, Providence, RI 02925, USA
    Gynecol Oncol 110:196-201. 2008
    ..The objectives of this study were to examine the levels of several novel tumor markers HE4, SMRP, CA72.4 and CA125 as potential markers in patients diagnosed with endometrioid adenocarcinoma of the uterus...
  65. ncbi Catecholestrogens induce oxidative stress and malignant transformation in human endometrial glandular cells: protective effect of catechol-O-methyltransferase
    Salama A Salama
    Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX 77555 0587, USA
    Int J Cancer 123:1246-54. 2008
    ....
  66. ncbi Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells
    Kendra S Carmon
    University of Texas Health Science Center Houston, 6431 Fannin Street, MSB 5 132A, Houston, TX 77030, USA
    Mol Cancer Res 6:1017-28. 2008
    ..These findings support a mechanism by which the nature of the Wnt7a signal in the endometrium is dependent on the Fzd repertoire of the cell and can be regulated by SFRP4...
  67. ncbi MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers
    R Luthra
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
    Oncogene 27:6667-78. 2008
    ..This study demonstrated a novel mechanism of post-transcriptional regulation of ANXA1 expression and identified miR-196a as a marker of esophageal cancer...
  68. ncbi Abrogation of estrogen receptor signaling augments cytotoxicity of anticancer drugs on CaSki cervical cancer cells
    Moon Y Heo
    College of Pharmacy, Kangwon National University, Chuncheon, Korea
    Anticancer Res 28:2181-7. 2008
    ..We investigated the mechanisms for enhanced cell killing when DN was combined with cisplatin (CP) and paclitaxel (TX)...
  69. ncbi Application of DNA methylation biomarkers for endometrial cancer management
    Shi Wen Jiang
    Department of Biomedical Science, Mercer University School of Medicine at Savannah, 4700, Waters Avenue, Savannah, GA 31404, USA
    Expert Rev Mol Diagn 8:607-16. 2008
    ..This disease is particularly well suited for such a strategy given that the endometrium is readily accessible for testing and endometrial cancer precursors are well defined...
  70. pmc beta-catenin mediates glandular formation and dysregulation of beta-catenin induces hyperplasia formation in the murine uterus
    J W Jeong
    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Oncogene 28:31-40. 2009
    ..Therefore, we have demonstrated that correct regulation of beta-catenin is important for uterine function as well as in the regulation of endometrial epithelial differentiation...
  71. pmc Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome
    Shannon N Westin
    Department of Gynecologic Oncology and Division of Quantitative Sciences, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 26:5965-71. 2008
    ..We performed a case-comparison study to document the clinicopathologic characteristics of LUS tumors and their association with risk factors for endometrial cancer...
  72. pmc Enhanced estrogen-induced proliferation in obese rat endometrium
    Qian Zhang
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Am J Obstet Gynecol 200:186.e1-8. 2009
    ..We tested the hypothesis that the proliferative estrogen effect on the endometrium is enhanced in obese vs lean animals...
  73. ncbi Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma
    Lois M Ramondetta
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas
    Cancer 115:1867-74. 2009
    ..The objective of this study was to determine the efficacy of mifepristone (RU-486) in women with advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma (LGESS)...
  74. ncbi DNA methylation inhibits p53-mediated survivin repression
    N H Nabilsi
    Department of Integrative Biology and Pharmacology, University of Texas Health Science Center Houston, Houston, 77030, USA
    Oncogene 28:2046-50. 2009
    ..However, our results indicate that an additional important mechanism is to decrease the expression of oncogenes...
  75. pmc EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer
    Aparna A Kamat
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 115:2684-92. 2009
    ..The objective of the current investigation was to study the role of EphA2 in endometrial cancer and its relation to steroid hormone receptor expression...
  76. ncbi MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents
    Dawn R Cochrane
    Department of Pathology, University of Colorado Denver School of Medicine, Aurora, Colorado 80045, USA
    Mol Cancer Ther 8:1055-66. 2009
    ..Because miR-200c is crucial for maintenance of epithelial identity, behavior, and sensitivity to chemotherapy, we propose that it warrants further investigation as a therapeutic strategy for aggressive, drug-resistant cancers...
  77. pmc Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease
    Jae Wook Jeong
    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 106:8677-82. 2009
    ..Since Mig-6 is regulated by both PR and SRC-1, this identifies a PR, SRC-1, Mig-6 regulatory pathway that is critical in the suppression of endometrial cancer...
  78. ncbi ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease
    Meenakshi Singh
    Department of Pathology, University of Colorado Health Sciences Center, Aurora, CO 80045, USA
    Mod Pathol 21:912-23. 2008
    ..It may help identify women who would most benefit from chemotherapy. Furthermore, if expression of ZEB1 in type II endometrial cancers could be reversed, it might be exploited as therapy for these highly aggressive tumors...
  79. ncbi Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma
    Karen H Lu
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Smithville, Texas 78957, USA
    Clin Cancer Res 14:2543-50. 2008
    ....
  80. ncbi Deregulation of the HOXA10 homeobox gene in endometrial carcinoma: role in epithelial-mesenchymal transition
    Hiroyuki Yoshida
    Department of Molecular Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 66:889-97. 2006
    ..These findings reveal a novel role for HOXA10 deregulation in the progression of endometrial carcinoma by promoting epithelial-mesenchymal transition...
  81. ncbi The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers
    Nicole S Spoelstra
    Department of Medicine, Division of Endocrinology, University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO 80045, USA
    Cancer Res 66:3893-902. 2006
    ....
  82. ncbi Women with HNPCC: a target population for the chemoprevention of gynecologic cancers
    Russell R Broaddus
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Front Biosci 11:2077-80. 2006
    ..The purpose of this review is to provide an analytical background about the current knowledge regarding gynecological cancers in patients with HNPCC...
  83. ncbi Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: Correlation with clinicopathologic parameters and biomarkers
    Nicole N Balmer
    Department of Pathology, University of Colorado Health Sciences Center, Denver, CO 80045, USA
    Mod Pathol 19:1593-605. 2006
    ..Future studies correlating expression with response to hormonal therapy may be beneficial...
  84. ncbi Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium
    Adrienne S McCampbell
    Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, Texas 77030, USA
    Clin Cancer Res 12:6373-8. 2006
    ..Although there is considerable information on the molecular aberrations associated with endometrial cancer, very little is known of the changes in gene expression associated with endometrial hyperplasia...
  85. pmc Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells
    Shujuan Jiang
    Shandong Provincial Hospital, Jinan, P R China
    Gynecol Oncol 105:493-500. 2007
    ..To characterize the molecular pathways involved in apoptosis following administration of histone deacetylase inhibitors to Type I and II endometrial cancer cells...
  86. ncbi Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats
    Nicholas J Laping
    GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, USA
    Clin Cancer Res 13:3087-99. 2007
    ....
  87. ncbi Hypomethylation-induced expression of S100A4 in endometrial carcinoma
    Ran Xie
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
    Mod Pathol 20:1045-54. 2007
    ..These results support the emerging concept that hypomethylation may play a role in the upregulation of genes during later stages of tumorigenesis...
  88. ncbi Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer
    Karen H Lu
    Department of Gynecologic Oncology, Division of Surgery, The University of Texas M D Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030 4009, USA
    J Clin Oncol 25:5158-64. 2007
    ..The purpose of this study was to determine the prevalence of MLH1, MSH2, and MSH6 mutations in an unselected cohort of women diagnosed with endometrial cancer at age younger than 50 years...
  89. ncbi Generation of a Mig-6 conditional null allele
    Nili Jin
    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
    Genesis 45:716-21. 2007
    ..In addition, these mice also had enlarged uteri with endometrial hyperplasia. In summary, this Mig-6(f/f) mouse is a useful tool for the functional study of the Mig-6 gene in a tissue-specific fashion...
  90. ncbi Progesterone-mediated regulation of catechol-O-methyl transferase expression in endometrial cancer cells
    Sana M Salih
    Department of Obstetrics and Gynecology, University of Wisconsin, Madison, Wisconsin, USA
    Reprod Sci 15:210-20. 2008
    ..These data suggest that COMT expression is hormonally regulated in well-differentiated human endometrial cancer cells. COMT regulation and 2-ME2 production in the endometrium may affect endometrial carcinogenesis...
  91. pmc Wnt7a interaction with Fzd5 and detection of signaling activation using a split eGFP
    Kendra S Carmon
    Department of Integrative Biology and Pharmacology, University of Texas Health Science Center Houston, 6431 Fannin Street, Houston, TX 77030, USA
    Biochem Biophys Res Commun 368:285-91. 2008
    ..These biological tools could help lead to a better understanding of Wnt-Fzd interactions and the identification of new modulators of Wnt signaling...
  92. ncbi Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas
    Cristina M Contreras
    Department of Pathology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9072, USA
    Cancer Res 68:759-66. 2008
    ..This study shows that Lkb1 plays an important role in the malignant transformation of endometrium and that Lkb1 loss promotes a highly invasive phenotype...
  93. ncbi Developmental reprogramming of IGF signaling and susceptibility to endometrial hyperplasia in the rat
    Adrienne S McCampbell
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Lab Invest 88:615-26. 2008
    ....
  94. pmc S100A4 mediates endometrial cancer invasion and is a target of TGF-beta1 signaling
    Ran Xie
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Lab Invest 89:937-47. 2009
    ..These results also suggest that endometrial cancer cell invasion and fibrosis share common molecular mechanisms...
  95. pmc Ablation of Indian hedgehog in the murine uterus results in decreased cell cycle progression, aberrant epidermal growth factor signaling, and increased estrogen signaling
    Heather L Franco
    Departments of Molecular and Cellular Biology and Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
    Biol Reprod 82:783-90. 2010
    ..Thus, Ihh regulates embryo implantation by having an impact on the cell cycle, EGF signaling, and E2 signaling...
  96. pmc Chitosan hydrogel for localized gene silencing
    Hee Dong Han
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 11:839-45. 2011
    ..To achieve effective delivery of siRNA into target cells in vivo, we have developed a novel approach of siRNA delivery by using local drug delivery systems...
  97. pmc Stress influences on anoikis
    Anil K Sood
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Cancer Prev Res (Phila) 4:481-5. 2011
    ..This review provides an overview of the relationship between psychosocial factors and the avoidance of anoikis by cancer cells...
  98. pmc Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer
    Pablo E Vivas-Mejia
    University of Puerto Rico Comprehensive Cancer Center Department of Biochemistry, University of Puerto Rico, Medical Science Campus, San Juan, Puerto Rico
    Clin Cancer Res 17:3716-26. 2011
    ..To study the role of survivin and its splice variants in taxane-resistant ovarian cancer...
  99. pmc MicroRNA therapeutics: principles, expectations, and challenges
    Rajesha Rupaimoole
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Chin J Cancer 30:368-70. 2011
    ..To overcome this limitation, delivery systems for miRNA-based therapeutic agents have been developed, which hold tremendous potential for improving therapeutic outcome of cancer patients...

Research Grants31

  1. Rocky Mountain Regional Center of Excellence or Biodefense and Emerging Infectiou
    John T Belisle; Fiscal Year: 2013
    ..abstract_text> ..
  2. DF/HCC Kidney Cancer SPORE
    David McDermott; Fiscal Year: 2013
    ..The overall goal of the DF/HCC Kidney Cancer SPORE is the translation of biological and technological advances into clinically meaningful advances for patients with kidney cancer. ..